Get ready!!We made a super nice five wave structure and are now in a corrective pattern. A buy between the .5 and .618 Fib retracement.
Key stats
Market capitalization
7.154MUSD
Dividends yield (FY)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.8859USD
About Cyclacel Pharmaceuticals, Inc
ISIN
US23254L6039
Sector
Health Technology
Industry
Pharmaceuticals: Major
Website
cyclacel.com
CEO
Spiro Rombotis
Headquarters
Berkeley Heights
Founded
1996
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.
Income Statement
Balance Sheet
Cash Flow
Earnings
Next:—
0
Revenue
0